FDA
-
-
-
-
-
-
-
Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis
-
-
-
-
-
-
-
Sagimet Biosciences (SGMT) Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis
-
-
-
-
-
-
-
Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference
-
-
-
-
-
-
-
TD Cowen Reiterates Buy Rating on Sagimet Biosciences Inc (SGMT)
-
-
-
329,911 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

